Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody

康宁杰瑞制药宣布与上海巴斯德合作开发用于冠状病毒治疗的抗体

2020-06-10 10:00:59 CISION

本文共2318个字,阅读需6分钟

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. , a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur of Shanghai, Chinese Academy of Sciences on the co-development, manufacturing and commercialization of therapeutic antibody for Corona Virus Disease 2019 worldwide. According to a report on June 8, more than 7.10 million people have been diagnosed with COVID-19 infection worldwide, but there are still no vaccines or medicines available for prevention or treatment. Neutralizing antibody targeting proteins on the surface of virus can effectively inhibit the virus' binding and entry into target cells to block infection, therefore it can be considered to be useful to protect or treat patients with COVID-19 infection. Among various potential solutions, the optimized mixed antibodies solution not only amplify the therapeutic effect due to synergistic effect, but also can solve the virus escaping issue due to COVID-19 virus' mutation, and minimizes the risk of "Antibody-dependent enhancement". This cooperation will fully leverage not only Institut Pasteur Shanghai 's prowess in research and development, and prior research findings in the area of infectious diseases, but also Alphamab Oncology's strong R&D and its proprietary Mixed Antibodies Platform, to develop COVID-19 neutralizing antibody with good safety and high neutralizing activity, complete clinical trials soon to provide antibody treatment options, effectively improve the prevention capabilities, reduce the mortality rate, and contribute to disease prevention and control for China and the world. Meanwhile, Pasteur's global R&D network could also help expedite the completion of clinical trial. According to the agreement, Alphamab Oncology and Institut Pasteur Shanghai will form a joint project team. Alphamab Oncology is responsible for providing its proprietary Mixed Antibodies Platform, constructing humanized antibodies and recombinant engineered cell lines, carrying out PK study, clinical trials, manufacturing, and commercialization. Institut Pasteur Shanghai is responsible for the comprehensive analysis of neutralizing activity of COVID-19 antibodies. Dr. Ting Xu, Founder, Chairman and CEO of Alphamab Oncology commented, "Since the end of 2019, COVID-19 has ravaged the world and has become the major global public health issue. We plan to partner with Institut Pasteur Shanghai by leveraging our proprietary antibody technology platform, extensive experiences in antibody drug R&D and established manufacturing platform to accelerate the development of COVID-19 antibodies to combat COVID-19, prevent subsequent outbreaks and contribute to the further prevention and control of this epidemic." Dr. Hong Tang, Director General and Legal Representative of Institut Pasteur Shanghai commented, "Since the outbreak of the Coronavirus, the Institut Pasteur Shanghai has been focusing on R&D Projects including virus detection and origin tracing, antibody drug and vaccine, and has achieved quite a few progress. This partnership with Alphamab Oncology on COVID-19 neutralizing antibody drug has demonstrated not only the innovation capability of our research and development team, but also a result of the reform of Chinese Academy of Sciences and the capable platform of Shanghai Science and Innovation Center. Our institute will collaborate with industry players to accelerate drug development and contribute to the prevention and control of pandemic as soon as possible." About Alphamab Oncology Alphamab Oncology is a biopharmaceutical company focusing on innovative biologics medicine for oncology. On December 12, 2019, the Company was listed in the mainboard of Hong Kong Stock Exchange with stock code 9966. Alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. Its highly differentiated in-house pipeline consists of eight anti-cancer drug candidates, four of which have advanced into Phase I – III clinical development phases in China, US and Japan. The Company also has state-of-the-art manufacturing capability designed and built to meet NMPA and EU/FDA's cGMP standards. Alphamab Oncology is committed to further develop its robust pipeline in oncology/immunology to benefit patients around the world. Visit http://www.alphamabonc.com for more information. About Institut Pasteur Shanghai Institut Pasteur of Shanghai of Chinese Academy of Sciences was established in October 11, 2004. It is the only national research institute dedicated to the basic research and development of relevant technologies for human infectious diseases within the Academy. The Institute focuses on key scientific subject such as the fundamental laws of pathogenic microorganisms' activities, and the pathogenic mechanism of major infectious diseases, to promotes the innovation and development of etiology, immunology and vaccinology to solve key issues such as the discovery of pathogen and biological treatment (antibodies, vaccines, etc. ), with a focus on providing scientific and technological support and solutions for public health and biosecurity of China. It is actively participating the building of Shanghai Science and Innovation Center. The infectious diseases' prevention and treatment platform, a functional platform which it is responsible for, will provide solid scientific support for the prevention and control of infectious diseases in Shanghai and Yangtze River Delta Region in China. Alphamab Oncology Forward-Looking Statements This press release contains statements related to our future business and financial performance and future events or developments involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Alphamab Oncology's management and business operation, many of which are difficult to predict and generally beyond Alphamab Oncology's control. These are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Alphamab Oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and Alphamab Oncology's disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Other than as required by applicable law, Alphamab Oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. SOURCE Alphamab Oncology
Alphamab Oncology 宣布,本公司全资子公司江苏 Alphamab Biopharma Pharmaceuticals Co ., Ltd 已与中国科学院上海巴斯德研究所就2019年全球范围内冠状病毒疾病治疗性抗体的共同开发、制造和商业化签订合作协议。 根据6月8日的一份报告,全球已有710多万人被诊断为 COVID-19感染,但仍没有疫苗或药品可用于预防或治疗。中和抗体靶向蛋白在病毒表面可以有效抑制病毒的结合并进入目标细胞阻止感染,因此可以认为对保护或治疗 COVID-19感染患者有用。在各种潜在的解决方案中,优化的混合抗体方案不仅放大了协同效应带来的治疗效果,而且可以解决 COVID-19病毒突变导致的病毒逃逸问题,最大限度地降低“抗体依赖性增强”的风险。 本次合作将充分发挥上海巴斯德研究所在传染病领域的研发实力和现有研究成果,以及 Alphamab 肿瘤学强大的研发和专有的混合抗体平台,开发安全性好、中和活性高的 COVID-19中和抗体,尽快完成临床试验,提供抗体治疗方案,有效提高预防能力,降低死亡率,为中国和世界疾病预防控制做出贡献。同时,巴斯德的全球研发网络也有助于加快临床试验的完成。 根据协议, Alphamab 肿瘤与上海巴斯德研究所将组建联合项目组。阿尔法肿瘤负责提供其专有的混合抗体平台,构建人源化抗体和重组工程细胞株,进行 PK 研究、临床试验、制造和商业化。上海巴斯德研究所负责全面分析 COVID-19抗体的中和活性。 Alphamab 肿瘤学创始人、董事长兼首席执行官 Ting Xu 博士评论称:“自2019年底以来, COVID-19席卷全球,已成为全球主要的公共卫生问题。我们计划与巴斯德研究所( Institut Pasteur Shanghai )合作,利用我们的专有抗体技术平台、丰富的抗体药物研发经验,并建立制造平台,加速 COVID-19抗体的开发,以抗击 COVID-19。预防随后的疫情,并有助于进一步预防和控制这一流行病。” 上海巴斯德研究所所长兼法律代表洪堂博士评论说:“自冠状病毒爆发以来,上海巴斯德研究所一直专注于包括病毒检测和起源追踪、抗体药物和疫苗在内的研发项目,并取得了相当多的进展。本次与 Alphamab 肿瘤学在 COVID-19中和抗体药物方面的合作,不仅体现了我们研发团队的创新能力,也是中国科学院改革的结果和上海科技创新中心的能力平台。我们的研究所将与业界人士合作,加速药物开发,并尽快为预防和控制大流行作出贡献。” 关于 Alphamab 肿瘤学 阿尔法肿瘤是一家生物制药公司,专注于肿瘤的创新生物医药。2019年12月12日,本公司在香港联交所主板上市,股票代码9966。 Alphamab 在双特异性和蛋白质工程方面完全集成了专有生物技术平台。其高度分化的内部管道由8个抗肿瘤药物候选者组成,其中4个已进入中国、美国和日本 I-III 期临床开发阶段。 该公司还拥有最先进的制造能力设计和建设,以满足 NMPA 和欧盟/ FDA 的 cGMP 标准。 阿尔法肿瘤致力于进一步发展其强大的肿瘤/免疫学管道,使世界各地的患者受益。详情请访问 http://www.alphahamabanc.com 。 关于上海巴斯德学院 中国科学院上海巴斯德研究所成立于2004年10月11日。它是学院内唯一一个致力于人类传染病相关技术的基础研究和开发的国家研究所。本所重点关注病原微生物活动的基本规律、重大传染病的致病机理等关键科学课题,推动病原学、免疫学、疫苗学的创新与发展,解决病原学发现、生物治疗(抗体)等关键问题;疫苗等),重点为中国的公共卫生和生物安全提供科技支持和解决方案。积极参与上海科技创新中心建设。传染病防治平台是其负责的功能平台,将为我国上海和长三角地区传染病防治工作提供坚实的科学支撑。 Alphamab 肿瘤学前瞻性陈述 本新闻稿包含有关我们未来业务及财务表现以及涉及 Alphamab 肿瘤的未来事件或发展的声明,可能构成前瞻性声明。这些报表包括预测和估计及其基本假设、关于未来财务业绩、事件、业务、服务、产品开发和潜力的计划、目标、意图和预期的报表,以及关于未来业绩的报表。这些陈述可以用“期待”、“期待”、“预期”、“打算”、“计划”、“相信”、“寻求”、“估计”、“将”、“项目”或类似含义的词语来识别。我们还可以在其他报告、演示文稿、提交股东的材料和新闻稿中发表前瞻性声明。此外,我们的代表可不时作口头的前瞻性发言。该等陈述基于 Alphamab 肿瘤管理层及业务经营目前的预期及若干假设,其中许多难以预测,且一般超出 Alphamab 肿瘤的控制范围。这些风险和不确定性包括但不限于研究和开发固有的不确定性、未来临床数据和分析、监管机构关于是否以及何时批准任何可能为任何此类产品候选者申请的药物、装置或生物应用的决定。没有保证产品候选人如果获得批准将在商业上获得成功,治疗替代品的未来批准和商业成功, Alphamab 肿瘤学从外部增长机会中获益的能力,汇率和现行利率的趋势,成本控制政策及其后续变化的影响,未发行股票的平均数量和 Alphamab 肿瘤学的披露。如果这些风险或不确定因素中的一个或多个发生,或者根本预期不发生或假设证明不正确, Alphamab 肿瘤学的实际结果、表现或成就可能(负面或正面)与相关前瞻性声明中明确或暗示描述的结果或成就存在重大差异。除适用法律要求外, Alphamab 肿瘤学不承担因新信息、未来事件或其他原因而公开更新任何前瞻性声明的义务。 SOURCE 阿尔法肿瘤学

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文